Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban

References

• Iorio R, Robb WJ, Healy WL et al. Orthopaedic surgeon workforce and volume assessment for total hip and knee replacement in the United States: preparing for an epidemic. J. Bone Joint Surg. Am.90(7), 1598–1605 (2008).
   PubMedGoogle Scholar
• Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J. Bone Joint Surg. Am.89(4), 780–785 (2007).
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest133(6 Suppl.), 381S–453S (2008).
   PubMed Web of Science ®Google Scholar
• Lang I, Kerr K. Risk factors for chronic thromboembolic pulmonary hypertension. Proc. Am. Thorac. Soc.3(7), 568–570 (2006).
   PubMedGoogle Scholar
• Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med.350(22), 2257–2264 (2004).
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC. Prevention of venous thromboembolism: clinical and economic implications. Introduction. Am. J. Health Syst. Pharm.63(20 Suppl. 6), S3–S4 (2006).
   PubMedGoogle Scholar
• Weitz JI. Low-molecular-weight heparins. N. Engl. J. Med.337(10), 688–698 (1997).
   PubMed Web of Science ®Google Scholar
• Spiro TE, Johnson GJ, Christie MJ et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group. Ann. Intern. Med.121(2), 81–89 (1994).
   PubMed Web of Science ®Google Scholar
• Camporese G, Bernardi E, Prandoni P et al. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann. Intern. Med.149(2), 73–82 (2008).
   PubMed Web of Science ®Google Scholar
• Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am. J. Health Syst. Pharm.58(Suppl. 2), S14–S17 (2001).
   PubMedGoogle Scholar
• Bauer KA, Hawkins DW, Peters PC et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents – the selective factor Xa inhibitors. Cardiovasc. Drug Rev.20(1), 37–52 (2002).
   PubMedGoogle Scholar
• Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest133(6 Suppl.), 160S–198S (2008).
   PubMed Web of Science ®Google Scholar
• Nicolaides AN, Breddin HK, Fareed J et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int. Angiol.20(1), 1–37 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry. Chest124(6 Suppl.), 349S–356S (2003).
   PubMed Web of Science ®Google Scholar
• Comp PC, Spiro TE, Friedman RJ et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J. Bone Joint Surg. Am.83-A(3), 336–345 (2001).
   PubMed Web of Science ®Google Scholar
• White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch. Intern. Med.158(14), 1525–1531 (1998).
   PubMed Web of Science ®Google Scholar
• Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest124(6 Suppl.), 386S–392S (2003).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Mancini GB, Biagini D. The rationale for long-term prophylaxis of venous thromboembolism. Orthopedics23(6 Suppl.), S643–S646 (2000).
   PubMed Web of Science ®Google Scholar
• Warwick D, Friedman RJ, Agnelli G et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J. Bone Joint Surg. Br.89(6), 799–807 (2007).
   PubMed Web of Science ®Google Scholar
• Friedman RJ. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J. Am. Acad. Orthop. Surg.15(3), 148–155 (2007).
   PubMed Web of Science ®Google Scholar
• Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J. Thromb. Haemost.5(8), 1610–1616 (2007).
   PubMed Web of Science ®Google Scholar
• Rahme E, Dasgupta K, Burman M et al. Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. CMAJ178(12), 1545–1554 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr. Global Orthopaedic Registry Investigators. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr. Med. Res. Opin.24(1), 87–97 (2008).
   PubMed Web of Science ®Google Scholar
• Caprini JA, Hyers TM. Compliance with antithrombotic guidelines: current practice, barriers, and strategies for improvement. Manag. Care15(9), 49–66 (2006).
   PubMedGoogle Scholar
• Borris LC. Barriers to the optimal use of anticoagulants after orthopaedic surgery. Arch. Orthop. Trauma Surg.129(11), 1441–1445 (2009).
   PubMed Web of Science ®Google Scholar
• Dahl OE, Bergqvist D. Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. Curr. Opin. Pulm. Med.8(5), 394–397 (2002).
   PubMed Web of Science ®Google Scholar
• Warwick D, Dahl OE, Fisher WD. Orthopaedic thromboprophylaxis: limitations of current guidelines. J. Bone Joint Surg. Br.90(2), 127–132 (2008).
   PubMedGoogle Scholar
• Levine MN, Gent M, Hirsh J et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch. Intern. Med.156(8), 851–856 (1996).
   PubMed Web of Science ®Google Scholar
• Kimmel SE, Chen Z, Price M et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch. Intern. Med.167(3), 229–235 (2007).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs66(11), 1411–1429 (2006).
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am. J. Health Syst. Pharm.58(Suppl. 2), S4–S13 (2001).
   PubMed Web of Science ®Google Scholar
• Friedman RJ. Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery. Thrombosis Article ID 108049 DOI: 10.1155/2010/108049 (2010).
   Google Scholar
• Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J. Manag. Care Pharm.11(8), 663–673 (2005).
   PubMedGoogle Scholar
• Muntz J, Scott DA, Lloyd A, Egger M. Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications. Int. J. Technol. Assess. Health Care20(4), 405–414 (2004).
   PubMed Web of Science ®Google Scholar
• Spyropoulos A, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J. Manag. Care Pharm.13(6), 475–486 (2007).
   PubMed Web of Science ®Google Scholar
• Hawkins D. Pharmacoeconomics of thrombosis management. Pharmacotherapy24(7 Pt 2), 95S–99S (2004).
   PubMed Web of Science ®Google Scholar
• de Lissovoy G. Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective. Am. J. Manag. Care7(17 Suppl.), S535–S538 (2001).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Kahn SR, Davidson BL, Borris L, Bossuyt P, Raskob G. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics21(7), 477–496 (2003).
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics20(9), 603–615 (2002).
   PubMed Web of Science ®Google Scholar
• Friedman RJ, Dunsworth GA. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. Clin. Orthop. Relat. Res.370, 171–182 (2000).
   PubMed Web of Science ®Google Scholar
• Caprini JA, Botteman MF, Stephens JM et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health6(1), 59–74 (2003).
   PubMed Web of Science ®Google Scholar
• Oster G, Ollendorf DA, Vera-Llonch M, Hagiwara M, Berger A, Edelsberg J. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann. Pharmacother.38(3), 377–382 (2004).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med.358(26), 2765–2775 (2008).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet372(9632), 31–39 (2008).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med.358(26), 2776–2786 (2008).
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet373(9676), 1673–1680 (2009).
   PubMed Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct factor Xa inhibitor. J. Thromb. Haemost.3(3), 514–521 (2005).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol.61(12), 873–880 (2005).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr. Med. Res. Opin.24(10), 2757–2765 (2008).
   PubMed Web of Science ®Google Scholar
• Depasse F, Busson J, Mnich J et al. Effect of BAY 59-7939 – a novel, oral, direct factor Xa inhibitor – on clot-bound factor Xa activity in vitro. J. Thromb. Haemost.3(Suppl. 1), abstract P1104 (2005).
   Google Scholar
• Perzborn E, Strassburger J, Wilmen A et al. Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct factor Xa inhibitor. Pathophysiol. Haemost. Thromb.33(Suppl. 2), abstract PO079 (2004).
   Google Scholar
• Fareed J, Hoppensteadt D, Maddenini J et al. Antithrombotic mechanism of action of BAY 59-7939 – a novel, oral, direct factor Xa inhibitor. J. Thromb. Haemost.3(Suppl. 1), abstract P0518 (2005).
   Google Scholar
• Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J. Thromb. Haemost.5(4), 886–888 (2007).
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Lassen MR, Eriksson BI et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost.105(3), 444–453 (2011).
   PubMed Web of Science ®Google Scholar
• Kwong LM, Duran A, Diamantopoulos A, Sengupta N, Lees M. Cost–effectiveness of rivaroxaban for prevention of venous thromboembolism (VTE) after total hip or knee replacement (THR, TKR) in the US. J. Thromb. Haemost.7(Suppl. 2), 787 (2009).
   PubMed Web of Science ®Google Scholar
• Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J. Association between asymptomatic deep-vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J. Thromb. Haemost.5(7), 1438–1443 (2007).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Villalta S, Bagatella P et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica82(4), 423–428 (1997).
   PubMed Web of Science ®Google Scholar
• McGarry LJ, Thompson D, Weinstein MC, Goldhaber SZ. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am. J. Manag. Care10(9), 632–642 (2004).
   PubMed Web of Science ®Google Scholar
• de Lissovoy G, Subedi P. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective. Am. J. Manag. Care8(12), 1082–1088 (2002).
   PubMed Web of Science ®Google Scholar
• Lin PJ. Reviewing the reality: why we need to change. Eur. Heart J. Suppl.7(Suppl. E), E15–E20 (2005).
   Web of Science ®Google Scholar
• Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J. Manag. Care Pharm.10(2), 159–165 (2004).
   PubMedGoogle Scholar
• Colwell CW Jr, Collis DK, Paulson R et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J. Bone Joint Surg. Am.81(7), 932–940 (1999).
   PubMed Web of Science ®Google Scholar
• Saunders ME, Grant RE. Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery. J. Natl Med. Assoc.90(11), 677–680 (1998).
   PubMed Web of Science ®Google Scholar
• Botteman MF, Caprini J, Stephens JM et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin. Ther.24(11), 1960–1986 (2002).
   PubMed Web of Science ®Google Scholar
• Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat. Med. J.51(2), 113–123 (2010).
   PubMed Web of Science ®Google Scholar
• Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism – systematic review and adjusted indirect comparison. J. Clin. Pharm. Ther.36(1), 111–124 (2011).
   PubMed Web of Science ®Google Scholar
• Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb. Haemost.104(1), 49–60 (2010).
   PubMed Web of Science ®Google Scholar
• Bauer KA. New oral anticoagulants in development: potential for improved safety profiles. Rev. Neurol. Dis.7(1), 1–8 (2010).
   PubMedGoogle Scholar
• Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med. Wkly139(5–6), 60–64 (2009).
   PubMed Web of Science ®Google Scholar
• Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr. Pharm. Des.16(31), 3436–3441 (2010).
   PubMed Web of Science ®Google Scholar
• Friedman RJ. New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty. Thrombosis Article ID 280731 DOI: 10.1155/2010/280731 (2010).
   Google Scholar
• Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood115(1), 15–20 (2010).
   PubMed Web of Science ®Google Scholar
• Paikin JS, Eikelboom JW, Cairns JA, Hirsh J. New antithrombotic agents – insights from clinical trials. Nat. Rev. Cardiol.7(9), 498–509 (2010).
   PubMed Web of Science ®Google Scholar
• Phillips KW, Ansell J. The clinical implications of new oral anticoagulants: will the potential advantages be achieved? Thromb. Haemost.103(1), 34–39 (2010).
   PubMed Web of Science ®Google Scholar
• Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb. Haemost.103(3), 572–585 (2010).
   PubMed Web of Science ®Google Scholar
• Verheugt FW. The new oral anticoagulants. Neth. Heart J.18(6), 314–318 (2010).
   PubMed Web of Science ®Google Scholar
• Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J. Thromb. Thrombolysis25(1), 52–60 (2008).
   PubMed Web of Science ®Google Scholar
• Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J. Thromb. Thrombolysis29(2), 182–191 (2010).
   PubMed Web of Science ®Google Scholar